Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 5/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20002451 | 0.94 | IDO1 (0.36) | IDO1TDO2BTKFNTAFNTB | |
| SCHEMBL20002003 | 0.89 | IDO1 (0.34) | IDO1TDO2BTKFNTAFNTB | |
| SCHEMBL21402087 | 0.89 | MAPK11 (0.36) | IDO1TDO2BTKCNR1 | |
| SCHEMBL21402085 | 0.89 | MAPK11 (0.36) | IDO1TDO2BTKCNR1 | |
| SCHEMBL21407497 | 0.89 | MAPK11 (0.36) | IDO1TDO2BTKCNR1 | |
| SCHEMBL20002464 | 0.88 | TLR9 (0.38) | TLR9TLR8TLR7NAMPTBTK | |
| SCHEMBL21402089 | 0.88 | CNR2 (0.39) | TLR9TLR8TLR7CNR2 | |
| SCHEMBL20042345 | 0.87 | EPHX2 (0.38) | IDO1TDO2BTK | |
| SCHEMBL20002503 | 0.86 | TLR9 (0.36) | TLR9TLR8TLR7NAMPTTDO2 | |
| SCHEMBL20001785 | 0.86 | TLR9 (0.36) | TLR9TLR8TLR7NAMPTTDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | PLEXXIKON INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | PLEXXIKON INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20190300487-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190300487-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-10-03 | — | — | US | disclosed |
| WO-2019183145-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | IDO1, TDO2, IDO2 | TLR9 1505/4885TLR8 1128/4885TLR7 1110/4885 |
| US-20190300487-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | TLR9 1505/4885TLR8 1128/4885TLR7 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.